Does managed care fuel pharmaceutical industry growth?

Michael Murray, Frank W. Deardorff

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Managed-care organisations and the pharmaceutical industry have diametrically opposing objectives, though there is hidden common ground. On one hand, most managed-care organisations now want to reduce the cost of drugs or at least maintain drug costs as a hedge against inflation. On the other, the pharmaceutical industry wants to sell more of their often expensive branded drug products in the setting of ever expanding managed care. This has sparked a variety of strategies aimed to meet objectives in what could be an endless game. Presently, this exchange is a dynamic process with shifts of momentum between managed-care organisations and the pharmaceutical industry. Forces that now favour the pharmaceutical industry's growth include movement of prescription payment from out-of-pocket to payment by insurers and the numbers of available innovative drug products. Common ground between managed care and the pharmaceutical industry may be found when more of both of their efforts are invested in investigating the effects of innovative drugs on total healthcare costs of patients. To date, available marketing data indicate that the pharmaceutical industry is fuelled by managed care, which is a somewhat ironic twist.

Original languageEnglish
Pages (from-to)341-348
Number of pages8
JournalPharmacoEconomics
Volume14
Issue number4
DOIs
StatePublished - 1998

Fingerprint

Drug Industry
Managed Care Programs
Growth
Drug Costs
Organizations
Pharmaceutical Preparations
Insurance Carriers
Economic Inflation
Health Expenditures
Marketing
Health Care Costs
Prescriptions

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Does managed care fuel pharmaceutical industry growth? / Murray, Michael; Deardorff, Frank W.

In: PharmacoEconomics, Vol. 14, No. 4, 1998, p. 341-348.

Research output: Contribution to journalArticle

Murray, Michael ; Deardorff, Frank W. / Does managed care fuel pharmaceutical industry growth?. In: PharmacoEconomics. 1998 ; Vol. 14, No. 4. pp. 341-348.
@article{3eaebb3a8c72415da36bf6e9f86c738a,
title = "Does managed care fuel pharmaceutical industry growth?",
abstract = "Managed-care organisations and the pharmaceutical industry have diametrically opposing objectives, though there is hidden common ground. On one hand, most managed-care organisations now want to reduce the cost of drugs or at least maintain drug costs as a hedge against inflation. On the other, the pharmaceutical industry wants to sell more of their often expensive branded drug products in the setting of ever expanding managed care. This has sparked a variety of strategies aimed to meet objectives in what could be an endless game. Presently, this exchange is a dynamic process with shifts of momentum between managed-care organisations and the pharmaceutical industry. Forces that now favour the pharmaceutical industry's growth include movement of prescription payment from out-of-pocket to payment by insurers and the numbers of available innovative drug products. Common ground between managed care and the pharmaceutical industry may be found when more of both of their efforts are invested in investigating the effects of innovative drugs on total healthcare costs of patients. To date, available marketing data indicate that the pharmaceutical industry is fuelled by managed care, which is a somewhat ironic twist.",
author = "Michael Murray and Deardorff, {Frank W.}",
year = "1998",
doi = "10.2165/00019053-199814040-00001",
language = "English",
volume = "14",
pages = "341--348",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Does managed care fuel pharmaceutical industry growth?

AU - Murray, Michael

AU - Deardorff, Frank W.

PY - 1998

Y1 - 1998

N2 - Managed-care organisations and the pharmaceutical industry have diametrically opposing objectives, though there is hidden common ground. On one hand, most managed-care organisations now want to reduce the cost of drugs or at least maintain drug costs as a hedge against inflation. On the other, the pharmaceutical industry wants to sell more of their often expensive branded drug products in the setting of ever expanding managed care. This has sparked a variety of strategies aimed to meet objectives in what could be an endless game. Presently, this exchange is a dynamic process with shifts of momentum between managed-care organisations and the pharmaceutical industry. Forces that now favour the pharmaceutical industry's growth include movement of prescription payment from out-of-pocket to payment by insurers and the numbers of available innovative drug products. Common ground between managed care and the pharmaceutical industry may be found when more of both of their efforts are invested in investigating the effects of innovative drugs on total healthcare costs of patients. To date, available marketing data indicate that the pharmaceutical industry is fuelled by managed care, which is a somewhat ironic twist.

AB - Managed-care organisations and the pharmaceutical industry have diametrically opposing objectives, though there is hidden common ground. On one hand, most managed-care organisations now want to reduce the cost of drugs or at least maintain drug costs as a hedge against inflation. On the other, the pharmaceutical industry wants to sell more of their often expensive branded drug products in the setting of ever expanding managed care. This has sparked a variety of strategies aimed to meet objectives in what could be an endless game. Presently, this exchange is a dynamic process with shifts of momentum between managed-care organisations and the pharmaceutical industry. Forces that now favour the pharmaceutical industry's growth include movement of prescription payment from out-of-pocket to payment by insurers and the numbers of available innovative drug products. Common ground between managed care and the pharmaceutical industry may be found when more of both of their efforts are invested in investigating the effects of innovative drugs on total healthcare costs of patients. To date, available marketing data indicate that the pharmaceutical industry is fuelled by managed care, which is a somewhat ironic twist.

UR - http://www.scopus.com/inward/record.url?scp=0031695075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031695075&partnerID=8YFLogxK

U2 - 10.2165/00019053-199814040-00001

DO - 10.2165/00019053-199814040-00001

M3 - Article

C2 - 10344902

AN - SCOPUS:0031695075

VL - 14

SP - 341

EP - 348

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 4

ER -